社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
稳稳稳稳稳
hehe
IP属地：未知
+关注
帖子 · 62
帖子 · 62
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
稳稳稳稳稳
稳稳稳稳稳
·
07-31
胡说八道呀
Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望
这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。与Trulicity组相比，该药物使用者的全因死亡率低16%。
Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望
看
265
回复
评论
点赞
1
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2024-12-12
$Bicycle Therapeutics Limited(BCYC)$
马上起飞，没人关注？
看
2,284
回复
1
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2024-07-11
$Cassava Sciences Inc(SAVA)$
几年前我说这是个骗子公司，一群人，特别某个所谓的大神，攻击说我是邪恶的空头。 [笑哭] 真的是 有些东西真的比所谓空头还恶心无脑。
看
3,949
回复
4
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2023-10-17
$Cassava Sciences Inc(SAVA)$
那个狗吹呢，最近怎么沉默了。 不是说如果sava造假就永久退出老虎的么？？？
看
3,543
回复
1
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2022-07-26
$Cassava Sciences Inc(SAVA)$
“只要不同意我意见的人，你就是邪恶的空头！”哈哈哈哈哈哈哈，真xx
看
3,003
回复
评论
点赞
1
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2022-04-05
$Cassava Sciences Inc(SAVA)$
不得不说 ，骗子洗脑真的有一套。 坏的都能往好的说，呵呵，丧尽天良，只能说
看
3,487
回复
2
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2022-03-04
$Cassava Sciences Inc(SAVA)$
真的菜🐔，自己去看看有没有别的biotech 会把fda hold写进自己10k的？？？？sava的管理者明白自己在做什么，只是给自己留条后路而已。真的是嘴硬，low bitc*！
看
2,773
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2022-03-03
$Cassava Sciences Inc(SAVA)$
居然水军还在吹这个股，真的是，不看科学药理，而天天在吹空头多不多，真是玩生化的天才呢。 好自为之
看
3,623
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2021-12-23
$Allakos Inc.(ALLK)$
别听楼上瞎说，公司cash value 在8刀+左右
看
7,221
回复
2
点赞
6
编组 21备份 2
分享
举报
稳稳稳稳稳
稳稳稳稳稳
·
2021-12-20
$Cassava Sciences Inc(SAVA)$
Remi这个骗子，劣迹斑斑，居然也有人信,真的是醉了。 不了解的自己去google下sava的前身 PITE 的事迹，简直了，呵呵 。 同一款药，被FDA拒了5次，还一直对投资者说我能行，问题不大[捂脸] [喷血] [喷血] [喷血] [喷血] [喷血]
看
6,620
回复
3
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3471744263113398","uuid":"3471744263113398","gmtCreate":1508651600892,"gmtModify":1623765239740,"name":"稳稳稳稳稳","pinyin":"wwwwwwenwenwenwenwen","introduction":"","introductionEn":null,"signature":"hehe","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":18,"headSize":13,"tweetSize":62,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.04.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":462688874021192,"gmtCreate":1753967014770,"gmtModify":1753967016408,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"胡说八道呀","listText":"胡说八道呀","text":"胡说八道呀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/462688874021192","repostId":"2555388898","repostType":2,"repost":{"id":"2555388898","kind":"news","pubTimestamp":1753963243,"share":"https://www.laohu8.com/m/news/2555388898?lang=&edition=full","pubTime":"2025-07-31 20:00","market":"sh","language":"zh","title":"Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望","url":"https://stock-news.laohu8.com/highlight/detail?id=2555388898","media":"智通财经","summary":"这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。与Trulicity组相比，该药物使用者的全因死亡率低16%。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/LLY\">礼来</a>(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。</p><p>这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。</p><p>虽然达到了这一目标，但研究结果打破了投资者对Mounjaro显著优于老药的期待。</p><p>分析师迈克尔·沙阿表示，<span>\"完全没有提及优效性——而礼来也确实进行了这项测试，\"</span>\"因此市场反应可能会很消极。\"</p><p>礼来的股价在纽约盘前交易中一度下跌5.3%，截至发稿，其跌幅收窄至1%。</p><p>这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药<span>Trulicity</span>。</p><p>Mounjaro在其他健康指标上表现更佳。与Trulicity组相比，该药物使用者的全因死亡率低16%。礼来表示，Mounjaro组患者在血糖控制、减重和降压方面改善更明显。两种药物最常见的不良反应均为轻度胃肠道症状。</p><p>Mounjaro使用者减重更多但心血管风险降幅相当的现象表明，这类被称为GLP-1的药物可能具有独立于减重效果的心脏保护作用。礼来将于9月在医学会议上公布完整研究，并计划年底前向全球药监机构提交新数据，以寻求将降低心血管风险纳入Mounjaro的适应症。</p><p>礼来心血管代谢业务总裁肯·卡斯特在声明中表示，<span>\"这些发现强化了Mounjaro作为2型糖尿病合并心血管疾病患者一线治疗选择的潜力。\"</span></p><p>Trulicity早在2020年就获得美国监管部门批准用于降低2型糖尿病患者主要心血管事件风险。</p><p>礼来与竞争对手<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>正竞相拓展旗下药物在糖尿病和减肥之外的适应症研究。虽然多数保险公司承保糖尿病治疗，但许多机构不愿覆盖减肥用途。诺和诺德已证实Ozempic和Wegovy均可降低肥胖和糖尿病患者的心血管事件风险，相关适应症标签使其在与保险机构和政府医保谈判中占据优势。</p><p>不过，即便未获批心血管适应症，礼来仍从诺和诺德手中夺取了可观市场份额。该公司并未专门针对减肥药Zepbound开展心血管风险研究，而是通过一项长达数年的大型试验评估其降低全因死亡率的效果，最终数据预计要到2027年才能出炉。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMounjaro心血管保护效果未超越Trulicity！礼来(LLY.US)令市场失望\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-31 20:00 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1324416.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1324416.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"http://www.zhitongcaijing.com/content/detail/1324416.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2555388898","content_text":"智通财经APP获悉，礼来(LLY.US)的明星糖尿病药物Mounjaro在一项针对两种治疗方法的正面对比研究中显示，其在预防心脏病发作和中风方面的效果与该公司老牌药物Trulicity基本相当。这项迄今为止礼来针对Mounjaro开展的规模最大、历时最长的试验，原本旨在证明该药物在降低主要心血管事件风险方面\"不劣于\"Trulicity，即希望表明Mounjaro是可接受的替代治疗方案。虽然达到了这一目标，但研究结果打破了投资者对Mounjaro显著优于老药的期待。分析师迈克尔·沙阿表示，\"完全没有提及优效性——而礼来也确实进行了这项测试，\"\"因此市场反应可能会很消极。\"礼来的股价在纽约盘前交易中一度下跌5.3%，截至发稿，其跌幅收窄至1%。这项试验纳入了13,000多名患有2型糖尿病且有心脏病史的患者，平均随访约四年期间，受试者分别接受Mounjaro或Trulicity治疗。礼来周四公布的结果显示，Mounjaro能有效降低心梗、中风和心血管死亡风险，但效果并未显著优于老药Trulicity。Mounjaro在其他健康指标上表现更佳。与Trulicity组相比，该药物使用者的全因死亡率低16%。礼来表示，Mounjaro组患者在血糖控制、减重和降压方面改善更明显。两种药物最常见的不良反应均为轻度胃肠道症状。Mounjaro使用者减重更多但心血管风险降幅相当的现象表明，这类被称为GLP-1的药物可能具有独立于减重效果的心脏保护作用。礼来将于9月在医学会议上公布完整研究，并计划年底前向全球药监机构提交新数据，以寻求将降低心血管风险纳入Mounjaro的适应症。礼来心血管代谢业务总裁肯·卡斯特在声明中表示，\"这些发现强化了Mounjaro作为2型糖尿病合并心血管疾病患者一线治疗选择的潜力。\"Trulicity早在2020年就获得美国监管部门批准用于降低2型糖尿病患者主要心血管事件风险。礼来与竞争对手诺和诺德正竞相拓展旗下药物在糖尿病和减肥之外的适应症研究。虽然多数保险公司承保糖尿病治疗，但许多机构不愿覆盖减肥用途。诺和诺德已证实Ozempic和Wegovy均可降低肥胖和糖尿病患者的心血管事件风险，相关适应症标签使其在与保险机构和政府医保谈判中占据优势。不过，即便未获批心血管适应症，礼来仍从诺和诺德手中夺取了可观市场份额。该公司并未专门针对减肥药Zepbound开展心血管风险研究，而是通过一项长达数年的大型试验评估其降低全因死亡率的效果，最终数据预计要到2027年才能出炉。","news_type":1,"symbols_score_info":{"LLY":1}},"isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":380623756603584,"gmtCreate":1733951135171,"gmtModify":1733951136912,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BCYC\">$Bicycle Therapeutics Limited(BCYC)$ </a> 马上起飞，没人关注？","listText":"<a href=\"https://laohu8.com/S/BCYC\">$Bicycle Therapeutics Limited(BCYC)$ </a> 马上起飞，没人关注？","text":"$Bicycle Therapeutics Limited(BCYC)$ 马上起飞，没人关注？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/380623756603584","isVote":1,"tweetType":1,"viewCount":2284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":326246322647136,"gmtCreate":1720651495828,"gmtModify":1720661975274,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$ </a> 几年前我说这是个骗子公司，一群人，特别某个所谓的大神，攻击说我是邪恶的空头。 [笑哭] 真的是 有些东西真的比所谓空头还恶心无脑。 ","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$ </a> 几年前我说这是个骗子公司，一群人，特别某个所谓的大神，攻击说我是邪恶的空头。 [笑哭] 真的是 有些东西真的比所谓空头还恶心无脑。 ","text":"$Cassava Sciences Inc(SAVA)$ 几年前我说这是个骗子公司，一群人，特别某个所谓的大神，攻击说我是邪恶的空头。 [笑哭] 真的是 有些东西真的比所谓空头还恶心无脑。","images":[{"img":"https://static.tigerbbs.com/7de8afd091084c0dedfde56a37ec28aa","width":"1170","height":"1328"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/326246322647136","isVote":1,"tweetType":1,"viewCount":3949,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3484536045691836","authorId":"3484536045691836","name":"科迪勒拉","avatar":"https://static.tigerbbs.com/856f04bd0b055f6769e058b1751b7600","crmLevel":7,"crmLevelSwitch":0,"idStr":"3484536045691836","authorIdStr":"3484536045691836"},"content":"你说的所谓的大神，就是指我吧？其实我最不喜欢这类称呼，先不说王博士是否有违法行为，我所讲的邪恶空头真的不是指你，你和我的影响力都太小了。我是指交请愿信的那帮人。","text":"你说的所谓的大神，就是指我吧？其实我最不喜欢这类称呼，先不说王博士是否有违法行为，我所讲的邪恶空头真的不是指你，你和我的影响力都太小了。我是指交请愿信的那帮人。","html":"你说的所谓的大神，就是指我吧？其实我最不喜欢这类称呼，先不说王博士是否有违法行为，我所讲的邪恶空头真的不是指你，你和我的影响力都太小了。我是指交请愿信的那帮人。"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":231473198985368,"gmtCreate":1697520878456,"gmtModify":1697520879561,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$ </a>那个狗吹呢，最近怎么沉默了。 不是说如果sava造假就永久退出老虎的么？？？","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$ </a>那个狗吹呢，最近怎么沉默了。 不是说如果sava造假就永久退出老虎的么？？？","text":"$Cassava Sciences Inc(SAVA)$ 那个狗吹呢，最近怎么沉默了。 不是说如果sava造假就永久退出老虎的么？？？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/231473198985368","isVote":1,"tweetType":1,"viewCount":3543,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":682395505,"gmtCreate":1658766979712,"gmtModify":1658766979712,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>“只要不同意我意见的人，你就是邪恶的空头！”哈哈哈哈哈哈哈，真xx","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>“只要不同意我意见的人，你就是邪恶的空头！”哈哈哈哈哈哈哈，真xx","text":"$Cassava Sciences Inc(SAVA)$“只要不同意我意见的人，你就是邪恶的空头！”哈哈哈哈哈哈哈，真xx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/682395505","isVote":1,"tweetType":1,"viewCount":3003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":619836993,"gmtCreate":1649168333841,"gmtModify":1649168864314,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>不得不说 ，骗子洗脑真的有一套。 坏的都能往好的说，呵呵，丧尽天良，只能说","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>不得不说 ，骗子洗脑真的有一套。 坏的都能往好的说，呵呵，丧尽天良，只能说","text":"$Cassava Sciences Inc(SAVA)$不得不说 ，骗子洗脑真的有一套。 坏的都能往好的说，呵呵，丧尽天良，只能说","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/619836993","isVote":1,"tweetType":1,"viewCount":3487,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4100833115172960","authorId":"4100833115172960","name":"Yaya2022","avatar":"https://static.tigerbbs.com/6109423acd9d5deb406b6d9a0113c17b","crmLevel":7,"crmLevelSwitch":0,"idStr":"4100833115172960","authorIdStr":"4100833115172960"},"content":"具体怎么说？谢谢。关注","text":"具体怎么说？谢谢。关注","html":"具体怎么说？谢谢。关注"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":632632547,"gmtCreate":1646382877761,"gmtModify":1646382877761,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>真的菜🐔，自己去看看有没有别的biotech 会把fda hold写进自己10k的？？？？sava的管理者明白自己在做什么，只是给自己留条后路而已。真的是嘴硬，low bitc*！","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>真的菜🐔，自己去看看有没有别的biotech 会把fda hold写进自己10k的？？？？sava的管理者明白自己在做什么，只是给自己留条后路而已。真的是嘴硬，low bitc*！","text":"$Cassava Sciences Inc(SAVA)$真的菜🐔，自己去看看有没有别的biotech 会把fda hold写进自己10k的？？？？sava的管理者明白自己在做什么，只是给自己留条后路而已。真的是嘴硬，low bitc*！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/632632547","isVote":1,"tweetType":1,"viewCount":2773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":632894531,"gmtCreate":1646322647727,"gmtModify":1646322647727,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>居然水军还在吹这个股，真的是，不看科学药理，而天天在吹空头多不多，真是玩生化的天才呢。 好自为之","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>居然水军还在吹这个股，真的是，不看科学药理，而天天在吹空头多不多，真是玩生化的天才呢。 好自为之","text":"$Cassava Sciences Inc(SAVA)$居然水军还在吹这个股，真的是，不看科学药理，而天天在吹空头多不多，真是玩生化的天才呢。 好自为之","images":[{"img":"https://static.tigerbbs.com/d1ee9f78b5a8c7b317d2f1d0f65a95f1","width":"1936","height":"362"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/632894531","isVote":1,"tweetType":1,"viewCount":3623,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":691210199,"gmtCreate":1640193843015,"gmtModify":1640193843015,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ALLK\">$Allakos Inc.(ALLK)$</a>别听楼上瞎说，公司cash value 在8刀+左右","listText":"<a href=\"https://laohu8.com/S/ALLK\">$Allakos Inc.(ALLK)$</a>别听楼上瞎说，公司cash value 在8刀+左右","text":"$Allakos Inc.(ALLK)$别听楼上瞎说，公司cash value 在8刀+左右","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/691210199","isVote":1,"tweetType":1,"viewCount":7221,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3543556603889775","authorId":"3543556603889775","name":"雨秋凉","avatar":"https://static.tigerbbs.com/fc6321217e26ab87ee9c9fcdd5696297","crmLevel":1,"crmLevelSwitch":0,"idStr":"3543556603889775","authorIdStr":"3543556603889775"},"content":"不太懂，什么意思","text":"不太懂，什么意思","html":"不太懂，什么意思"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693634243,"gmtCreate":1640012107161,"gmtModify":1640012107161,"author":{"id":"3471744263113398","authorId":"3471744263113398","name":"稳稳稳稳稳","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3471744263113398","authorIdStr":"3471744263113398"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Remi这个骗子，劣迹斑斑，居然也有人信,真的是醉了。 不了解的自己去google下sava的前身 PITE 的事迹，简直了，呵呵 。 同一款药，被FDA拒了5次，还一直对投资者说我能行，问题不大[捂脸] [喷血] [喷血] [喷血] [喷血] [喷血] ","listText":"<a href=\"https://laohu8.com/S/SAVA\">$Cassava Sciences Inc(SAVA)$</a>Remi这个骗子，劣迹斑斑，居然也有人信,真的是醉了。 不了解的自己去google下sava的前身 PITE 的事迹，简直了，呵呵 。 同一款药，被FDA拒了5次，还一直对投资者说我能行，问题不大[捂脸] [喷血] [喷血] [喷血] [喷血] [喷血] ","text":"$Cassava Sciences Inc(SAVA)$Remi这个骗子，劣迹斑斑，居然也有人信,真的是醉了。 不了解的自己去google下sava的前身 PITE 的事迹，简直了，呵呵 。 同一款药，被FDA拒了5次，还一直对投资者说我能行，问题不大[捂脸] [喷血] [喷血] [喷血] [喷血] [喷血]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/693634243","isVote":1,"tweetType":1,"viewCount":6620,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3547709823823428","authorId":"3547709823823428","name":"期权大作手","avatar":"https://static.tigerbbs.com/93604605a7259e122bfe86817850c1a0","crmLevel":1,"crmLevelSwitch":0,"idStr":"3547709823823428","authorIdStr":"3547709823823428"},"content":"应该到5块吧。","text":"应该到5块吧。","html":"应该到5块吧。"}],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}